J.W. Cole Advisors Inc. Sells 4,145 Shares of Bristol-Myers Squibb (NYSE:BMY)

J.W. Cole Advisors Inc. decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 17.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,862 shares of the biopharmaceutical company’s stock after selling 4,145 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $1,028,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. ESL Trust Services LLC acquired a new position in Bristol-Myers Squibb during the first quarter worth $27,000. LGT Financial Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 227 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth about $34,000. MFA Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb during the 2nd quarter valued at about $39,000. Finally, Beach Investment Counsel Inc. PA bought a new stake in Bristol-Myers Squibb during the 2nd quarter worth approximately $42,000. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Sanford C. Bernstein assumed coverage on Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 target price on the stock. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. BMO Capital Markets reissued a “market perform” rating and set a $48.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. TD Cowen increased their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $53.57.

Bristol-Myers Squibb Stock Down 0.2 %

BMY stock opened at $52.52 on Wednesday. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $55.03. The stock has a fifty day moving average of $50.89 and a 200-day moving average of $46.44. The company has a market capitalization of $106.46 billion, a price-to-earnings ratio of -16.94, a PEG ratio of 13.75 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.57%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.